The USD 119.6 support, currently tested, should allow United Therapeutics Corporation to rally again.

From a fundamental viewpoint, the security is cheap with a P/E Ratio of 9.16x for 2015 and 10.02x for 2016. Moreover the company has recorded a a growth or its revenues in the last years and that should continue in the next years.

Technically, the security fell sharply for several weeks. This fall has lead United Therapeutics Corporation towards the USD 119.57 support area, which could become useful as a stepping stone for a technical rebound. The target of this bullish trend is the USD 143.2 resistance. Even though moving averages are still in a bearish trend, the oversold situation could encourage a renewed interest in United Therapeutics Corporation.

Thanks to the technical pattern and United Therapeutics Corporation’s strong fundamentals, active investors can open long trades above USD 119.6. The downside potential is limited and the timing seems perfect to benefit from a technical rebound.
The goal will be fixed at USD 143.2 in a first time.
However, a bearish trend would regain the upper hand if the security crosses USD 119.6.